# Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

> **NCT07279532** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- Neuroendocrine Neoplasms (Tumours)

## Interventions

- **DRUG:** surufatinib

## Key facts

- **NCT ID:** NCT07279532
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07279532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07279532, "Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07279532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*